hydroxychloroquine

Ligand id: 7198

Name: hydroxychloroquine

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: hydroxychloroquine

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 48.39
Molecular weight 335.18
XLogP 3.14
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
Ligand families/groups Antimalarial ligands
Approved drug? Yes (FDA (1955))
WHO Essential Medicine WHO Model List of Essential Medicines (21st List, 2019). Access PDF version.
IUPAC Name
2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol
International Nonproprietary Names
INN number INN
796 hydroxychloroquine
Synonyms
Dolquine® | Plaquenil®
Comments
Hydroxychloroquine is a 4-aminoquinoline and used primarily as an antimalarial drug.
The approved drug is a racemic mixture and we show the chemical structure without stereochemistry to represent the mixture. The non-isomeric structure is also represented in the PubChem, ChEMBL and ChEBI entries listed in the links table below, while the two enantiomers forming the racemate are represented by PubChem CID 178395 and PubChem CID 178396.
The marketed formulations contain hydroxychloroquine sulfate (PubChem CID 3044369).

Activity at non-malarial protein targets:
Although this drug has direct effects on survival of the malaria parasite it also appears to be an antagonist of two of the human TOLL-like receptors (TLR7 and TLR9). Antagonism of these receptors is likely related to the anti-inflammatory action of this drug in some auto-immune diseases.

Activity against SARS-CoV-2:
Hydroxychloroquine exhibits in vitro antiviral activity against both the original SARS coronavirus (SARS-CoV) [1] and SARS-CoV-2 which emerged in 2019 [5]. Preliminary evidence from a small clinical trial indicates that hydroxychloroquine reduces detectable virus in COVID-19 patients, and that this effect is enhanced by co-treatment with the antibiotic azithromycin (article in press, to be published in International Journal of Antimicrobial Agents, available pre-release via DOI: 10.1016/j.ijantimicag.2020.105949. It is predicted that this effect could be the result of a combination of the drug's antiviral action and its established anti-inflammatory efficacy [2]. In addition to cardiovascular adverse effects associated with hydroxychloroquine (and also with chloroquine) treatment, another restriction to the widespread use of hydroxychloroquine against COVID-19 should be that there is as yet no convincing (statistically significant) evidence to support therapeutic or prophylactic efficacy against this infection. High quality randomised controlled studies will be an essential component of further clinical efforts.
Database Links
CAS Registry No. 118-42-3
ChEBI CHEBI:5801
ChEMBL Ligand CHEMBL1535
DrugBank Ligand DB01611
GtoPdb PubChem SID 178103773
PubChem CID 3652
Search Google for chemical match using the InChIKey XXSMGPRMXLTPCZ-UHFFFAOYSA-N
Search Google for chemicals with the same backbone XXSMGPRMXLTPCZ
Search PubMed clinical trials hydroxychloroquine
Search PubMed titles hydroxychloroquine
Search PubMed titles/abstracts hydroxychloroquine
Search UniChem for chemical match using the InChIKey XXSMGPRMXLTPCZ-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone XXSMGPRMXLTPCZ
Wikipedia Hydroxychloroquine

Product suppliers

View disclaimer

Tocris